4月30日公司发布的一季报数据显示，一季度公司共实现营业收入8.30亿元，同比增长3.46%，实现净利 润1.31亿元，同比下降1.47%。（数据宝） 福元医药6月18日交易公开信息 福元医药(601089)今日涨停，全天换手率6.99%，成交额2.62亿元，振幅10.94%。龙虎榜数据显示，机 构净买入1674.76万元，沪股通净卖出123.19万元，营业部席位合计净买入3853.68万元。 上交所公开信息显示，当日该股因日涨幅偏离值达9.99%上榜，机构专用席位净买入1674.76万元，沪股 通净卖出123.19万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.28亿元，其中，买入成交额为9110.53 万元，卖出成交额为3705.28万元，合计净买入5405.25万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即买四，合计净买入1674.76万元，沪股 通为第三大买入营业部及第一大卖出营业部，买入金额为1941.83万元，卖出金额为2065.02万元，合计 净卖出123.19万元。 资金流向方面，今日该股主力资金净流入6717.60万元，其中，特大单净流入7991.38 ...

Group 1 - The company Fengyuan Pharmaceutical (601089) is focusing on research and development, planning to increase R&D investment continuously [1] - The company's self-developed innovative drug FY101 injection is currently in Phase I clinical trials, with a target enrollment of 62 participants, of which 6 have been enrolled so far [1] - The company has received approval for 11 formulation varieties and 1 raw material drug this year, with 40 varieties under review by the National Medical Products Administration as of June 13, 2025 [1] - The failure to win the bid for the tenth batch of collective procurement of compound α-keto acid will have some impact on future sales, but it will not significantly affect the company's production and operations [1] - The company aims to expand sales in retail markets and other channels, leveraging continuous R&D to launch new products [1] - The retail market coverage includes top 100 chain pharmacies, regional chains, independent pharmacies, and community clinics nationwide [1] Group 2 - Pengyang Fund, established in 2016, has an asset management scale of 119.899 billion yuan, ranking 53rd out of 210 [2] - The asset management scale for non-monetary public funds is 106.687 billion yuan, ranking 45th out of 210 [2] - The fund manages 179 public funds, ranking 37th out of 210, with 24 fund managers, ranking 59th out of 210 [2] - The best-performing public fund product in the past year is Pengyang Beizheng 50 Index A, with a latest net value of 1.4 and a growth of 67.13% over the past year [2] - The latest public fund product raised by the company is Pengyang Heli Bond A, which is a mixed secondary bond type, with a subscription period from June 3, 2025, to September 2, 2025 [2]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

关于阿昔莫司胶囊获得药品注册证书的公告 证券代码：601089 证券简称：福元医药 公告编号：临 2025-045 北京福元医药股份有限公司 二、药品相关信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局(以下简称"国家药监局")颁发的阿昔莫司胶囊 （规格：0.25g）(以下简称"该药品")《药品注册证书》(证书编号： 2025S01693)，批准该药品生产。现将相关情况公告如下： 药品名称 药品通用名称：阿昔莫司胶囊 英文名/拉丁名：Acipimox Capsules 剂型 胶囊剂 注册分类 化学药品4类 规格 0.25g 药品批准文号 国药准字H20254442 药品注册标准编号 YBH12582025 申请事项 药品注册（境内生产） 审批结论 根据《中华人民共和国药品管理法》及有关规 定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说 明书、标签及生产工艺照所附执行。药品生产 企业应当符合药品生产质量管理规范 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-045 北京福元医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局(以下简称"国家药监局")颁发的阿昔莫司胶囊 （规格：0.25g）(以下简称"该药品")《药品注册证书》(证书编号： 2025S01693)，批准该药品生产。现将相关情况公告如下： 药品名称 药品通用名称：阿昔莫司胶囊 英文名/拉丁名：Acipimox Capsules 剂型 胶囊剂 注册分类 化学药品4类 规格 0.25g 药品批准文号 国药准字H20254442 药品注册标准编号 YBH12582025 申请事项 药品注册（境内生产） 审批结论 根据《中华人民共和国药品管理法》及有关规 定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准、说 明书、标签及生产工艺照所附执行。药品生产 企业应当符合药品生产质量管理规范要求方可 一、药品注册证书主要内容 | | 生产销售。 | ...

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

Group 1 - Baiyunshan received drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration, indicating its entry into the erectile dysfunction treatment market [1] - Huayin Power plans to invest approximately 1.398 billion yuan in three renewable energy projects with a total installed capacity of 230 MW [2] - GAC Group reported a 24.8% year-on-year decline in May automobile sales, with total sales of 117,700 units [3] Group 2 - Honghui Fruits and Vegetables announced a potential change in control due to share transfer negotiations, leading to a temporary suspension of its stock and convertible bonds [4] - Fuyuan Pharmaceutical's subsidiary received a drug registration certificate for Bromhexine Hydrochloride oral solution, aimed at treating respiratory diseases [5][6] - Jianghan New Materials plans to repurchase shares worth 200 million to 400 million yuan, with a maximum price of 30 yuan per share [7][8] Group 3 - Sinan Navigation received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau due to multiple issues in its 2024 annual report [9][10] - Hesheng Co. received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [11] - Daqin Railway reported a 1.85% year-on-year decrease in cargo transportation volume in May, totaling 32.96 million tons [13] Group 4 - Ningbo Construction's subsidiary won a design and construction project with a bid of 787 million yuan [14] - Yuehongyuan A announced the termination of a major asset restructuring plan due to failure to reach an agreement on key terms [15][16] - Mingyang Smart Energy reached a 190 million yuan repurchase agreement with Haiji New Energy [18] Group 5 - CNE Group's subsidiary plans to reduce registered capital from 430 million yuan to 330 million yuan [19] - ST Baili received an administrative penalty for failing to disclose non-operating fund occupation matters, resulting in a fine of 4 million yuan [21] - Baichuan Co. completed the repurchase of a 7.14% stake in its subsidiary for 50 million yuan [22] Group 6 - Dongrui Co. reported May sales of 155,400 pigs, generating revenue of 203 million yuan, a decrease of 8.77% month-on-month [25][26] - Pengding Holdings reported a 22.43% year-on-year increase in May consolidated revenue, totaling 2.598 billion yuan [27] - Dabeinong reported May sales of 727,600 pigs, with total revenue of 1.248 billion yuan [28] Group 7 - Lihua Co. reported a 4.77% year-on-year decrease in May chicken sales revenue, totaling 1.118 billion yuan [29][30] - Jindan Technology plans to use up to 300 million yuan of idle funds for entrusted wealth management [31] - Youxunda won a project from the State Grid worth approximately 176 million yuan [33][34] Group 8 - Shenglan Co. received approval for its convertible bond issuance from the Shenzhen Stock Exchange [35][36] - Jingfang Technology's shareholder plans to reduce holdings by up to 2% of the company's shares [37] - Shiji Information's subsidiary signed a significant contract with Marriott for cloud services [39] Group 9 - Northeast Securities' subsidiary plans to terminate its listing on the New Third Board [40] - Yaji International's supervisor is under investigation for insider trading [42][43] - Yian Technology signed a strategic cooperation framework agreement with Shenzhen Hive Interconnect Technology [44] Group 10 - Jinyu Group's subsidiary acquired a real estate project for 3.364 billion yuan [46][47] - Kaiweite's major shareholder plans to reduce holdings by up to 3% of the company's shares [48] - Ningbo Energy's subsidiary plans to publicly transfer fixed assets valued at approximately 17.4372 million yuan [49]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-044 北京福元医药股份有限公司 关于盐酸溴己新口服溶液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）全资子 公司福元药业有限公司（以下简称"福元药业"）收到了国家药品监 督管理局(以下简称"国家药监局") 颁发的盐酸溴己新口服溶液（规 格 1：40ml:80mg；规格 2：100ml:0.2g，以下简称"该药品"）《药 品注册证书》（证书编号：规格 1：2025S01639；规格 2：2025S01640）。 现将相关情况公告如下： 药品名称 药品通用名称：盐酸溴己新口服溶液 英文名/拉丁名：Bromhexine Hydrochloride Oral Solution 剂型 口服溶液剂 注册分类 化学药品3类 规格 （1）40ml:80mg；（2）100ml:0.2g 药品批准文号 （1）国药准字H20254392 （2）国药准字H20254393 药品注册标准编号 YBH1187 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received a drug registration certificate from the National Medical Products Administration for its oral solution of bromhexine hydrochloride, indicating a significant milestone in its product development and market entry [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted a registration certificate for bromhexine hydrochloride oral solution, with specifications of 40ml:80mg and 100ml:0.2g [1] - The drug is indicated for symptomatic treatment of respiratory diseases related to mucus secretion or clearance disorders in adults, adolescents, and children aged 6 and above [1] - The company invested a total of RMB 2.389 million in the research and development of this drug as of the announcement date [1] Industry Summary - According to data from Minet, the sales revenue of bromhexine hydrochloride oral solution in China's three major terminal markets is approximately RMB 18.57 million for 2024 [1] - The approval of this drug may enhance Fuyuan Pharmaceutical's competitive position in the respiratory treatment market [1]

近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）核准签发的酮洛芬 贴剂的《药物临床试验批准通知书》。现将有关情况公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：酮洛芬贴剂（以下简称"本品"） 通知书编号：2025LP01488、2025LP01489 制剂剂型：贴剂 申请适应症：①以下疾病和症状的镇痛、消炎：腰痛（肌肉或筋 膜性腰痛、变形性脊椎病、椎间盘疾病、腰椎挫伤）、骨关节炎、肩 周炎、肌腱及腱鞘炎、肌腱周围炎、肱骨外上髁炎（网球肘等）、肌 肉痛、创伤后肿胀疼痛。②类风湿性关节炎的关节局部镇痛。 注册分类：化学药品 3 类 证券代码：601089 证券简称：福元医药 公告编号：临 2025-043 北京福元医药股份有限公司 关于酮洛芬贴剂获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 申请事项：境内生产药品注册临床试验 申请人：北京福元医药股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，202 ...